| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/18/2023 | 314.75% | HC Wainwright & Co. | → $18 | Initiates Coverage On | → Buy |
What is the target price for AEON Biopharma (AEON)?
The latest price target for AEON Biopharma (AMEX: AEON) was reported by HC Wainwright & Co. on August 18, 2023. The analyst firm set a price target for $18.00 expecting AEON to rise to within 12 months (a possible 314.75% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AEON Biopharma (AEON)?
The latest analyst rating for AEON Biopharma (AMEX: AEON) was provided by HC Wainwright & Co., and AEON Biopharma initiated their buy rating.
When is the next analyst rating going to be posted or updated for AEON Biopharma (AEON)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AEON Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AEON Biopharma was filed on August 18, 2023 so you should expect the next rating to be made available sometime around August 18, 2024.
Is the Analyst Rating AEON Biopharma (AEON) correct?
While ratings are subjective and will change, the latest AEON Biopharma (AEON) rating was a initiated with a price target of $0.00 to $18.00. The current price AEON Biopharma (AEON) is trading at is $4.34, which is within the analyst's predicted range.